Feasibility study of using high-throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment.

Erlend SkagaEvgeny KulesskiyMarit BrynjulvsenCecilie J SandbergSwapnil PotdarIver A LangmoenAki LaaksoEmília Gaál-PaavolaMarkus PerolaKrister WennerbergEinar O Vik-Mo

Published in: Clinical and translational medicine (2019)

In recGBM, GSC cultures could successfully be established in the majority of patients. The individual cultures displayed intertumoral heterogeneity in their in vitro and in vivo behavior. Within a time frame for clinical application, we could perform DSRT in 50% of recGBM patients. The DSRT revealed a remarkable intertumoral heterogeneity in sensitivity to anticancer drugs in recGBM that could allow tailored therapeutic options for functional precision medicine.

Keyphrases

stem cells
end stage renal disease
high throughput
ejection fraction
single cell
newly diagnosed
chronic kidney disease
emergency department
mesenchymal stem cells
patient reported outcomes
smoking cessation